Arrowhead Pharmaceutical’s investigational RNA interference (RNAi) obesity candidate in combination with Eli Lilly’s Zepbound ...
Honeybees are vital to global food security, yet colony collapse threatens ecosystems and agriculture worldwide. Discover ...
RNA drugs are a new type of medicine that treat disease by influencing how cells use genetic information, rather than by ...
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from two Phase 1/2a clinical trials of ARO-INHBE and ARO-ALK7, the company’s investigational RNA interference (RNAi) ...
Company on track to report ELEVATE-44-201 data from the first cohort in Q2 2026 and ELEVATE-45-201 data from the first cohort in mid-2026 –-- ...
NEW YORK, July 21, 2021 /PRNewswire/ -- Mirimus, Inc., a pioneer in RNAi therapeutic design and CRISPR/Cas9 gene editing technology implementation, today announced a strategic collaboration with ...
Detailed price information for Arrowhead Pharma (ARWR-Q) from The Globe and Mail including charting and trades.
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (ARWR) today announced that preclinical data on ARO-INHBE, an investigational RNAi-based medicine for the treatment of obesity and ...
The technology, called the Viral-Engineered RNA-based Activation System (VERAS), hijacks the virus's own replication ...
Acuitas Therapeutics shelled out an undisclosed sum to acquire a majority stake in Montreal-based and privately held RNA Technologies & Therapeutics in a move to scale the latter’s operations around ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback